<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03712644</url>
  </required_header>
  <id_info>
    <org_study_id>30-194 ex 17/18</org_study_id>
    <nct_id>NCT03712644</nct_id>
  </id_info>
  <brief_title>Coronary Revascularization Versus Conservative Therapy in Patients With Treated Critical Limb Ischemia</brief_title>
  <acronym>INCORPORATE</acronym>
  <official_title>Intentional Coronary Revascularization Versus Conservative Therapy in Patients Undergoing Peripheral Artery Revascularization Due to Critical Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the INCORPORATE trial is to evaluate whether an intentional invasive
      strategy with ischemia targeted, reasonably complete coronary revascularization and optimal
      medical therapy is superior as compared to a primary conservative approach and optimal
      medical therapy alone in terms of spontaneous myocardial infarct-free and overall survival in
      patients with severe peripheral artery disease, underwent peripheral artery revascularization
      due to critical limb ischemia.

      The INCORPORATE trial is designed to be non-blinded, open-label, prospective 1:1 randomized
      controlled multicentric trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>non-blinded, open-label, prospective 1:1 randomized controlled multicentric trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of composite of overall death and spontaneous myocardial infarction</measure>
    <time_frame>1-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of composite of overall death and spontaneous myocardial infarction</measure>
    <time_frame>2-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of overall death</measure>
    <time_frame>1- and 2-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of spontaneous myocardial infarction</measure>
    <time_frame>1- and 2-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EQ5D) development</measure>
    <time_frame>1- and 2-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of composite of death, spontaneous myocardial infarction, target coronary revascularization and any stroke</measure>
    <time_frame>1- and 2-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of composite of death, spontaneous myocardial infarction, target coronary revascularization</measure>
    <time_frame>1- and 2-years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">650</enrollment>
  <condition>Obstructive Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Conservative</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive primarily optimal medical therapy alone and followed, according to protocol. Any further cardiologic investigation will be performed only in case of clinical suspicion of myocardial ischemia related symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Invasive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the Invasive group in addition to optimal medical therapy elective coronary angiography will be performed. Coronary catheterization is preferably scheduled within a maximum of 14 days after peripheral revascularization
All lesions of 50-90% diameter stenosis in a major coronary artery will be evaluated by fractional flow reserve (FFR) and intervened by percutaneous coronary intervention (PCI) if FFR≤0.80 or left for medical therapy if FFR&gt;0.80. All lesions of ≥90% diameter stenosis in a major coronary artery will be intervened. This includes also efforts to recanalize chronic total occlusions (CTO) of large supplied viable myocardial territory.
For complex cases revascularization by coronary artery bypass surgery might be considered, however PCI is preferred whenever possible.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FFR-guided coronary revascularization</intervention_name>
    <description>Stenoses in range of 50-90% diameter stenosis in major coronary arteries will be assessed by FFR, and revascularized if FFR equal to or lower than 0.80. Lesions above 90% diameter stenosis in will be revascularized without further assessment.</description>
    <arm_group_label>Invasive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients, undergoing successful peripheral revascularization (percutaneous or
             surgical) due to critical limb ischemia will be screened, and enrolled if informed
             consent form is signed and none of the following exclusion criteria is met.

        Exclusion Criteria:

          -  contraindication for double antiplatelet therapy for at least one month;

          -  contraindication for guideline-conform longterm antiplatelet/anticoagulation regime
             after PCI;

          -  heart failure with ejection fraction below 35%;

          -  significant valvular heart disease with indication for surgical or percutaneous
             repair;

          -  any concomitant disease with a life expectancy less than 2 years;

          -  severe renal dysfunction with glomerular filtration rate below 30 mL/min/1.73m2;

          -  ongoing sepsis.

        Patients, who cannot be enrolled for any reasons will enter a prospective registry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabor G Toth, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Div. Cardiology, Dept. Medicine, Medical University Graz, Graz, Austria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zoltan Ruzsa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bacs-Kiskun County Hospital, Kecskemet, Hungary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marianne Brodmann, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Div. Angiology, Dept. Medicine, Medical University Graz, Graz, Austria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gabor G Toth, MD, PhD</last_name>
    <phone>004331638512544</phone>
    <email>gabor.g.toth@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Peischl, BA</last_name>
    <phone>004331638581367</phone>
    <email>Nicole.Peischl@klinikum-graz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Div. Cardiology and Div. Angiology, Dept. Medicine, Medical University Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabor G Toth, MD, PhD</last_name>
      <phone>0043 316385 12 544</phone>
      <email>gabor.g.toth@medunigraz.at</email>
    </contact>
    <investigator>
      <last_name>Marianne Brodmann, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun County Hospital</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoltan Ruzsa, MD, PhD</last_name>
      <email>zruzsa25@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Hungary</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 17, 2018</study_first_submitted>
  <study_first_submitted_qc>October 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2018</study_first_posted>
  <last_update_submitted>November 3, 2018</last_update_submitted>
  <last_update_submitted_qc>November 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Graz</investigator_affiliation>
    <investigator_full_name>Gabor Toth-Gayor</investigator_full_name>
    <investigator_title>Staff-member interventional cardiologist</investigator_title>
  </responsible_party>
  <keyword>Critical limb ischemia</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>Fractional flow reserve-guided coronary revascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

